Table 1.
Overall baseline characteristics in the cohort stratified by therapeutic regimen
| Variables | All (n = 278) | Group 1 (n = 135) | Group 2 (n = 39) | Group 3 (n = 79) | Group 4 (n = 25) | P‐value |
|---|---|---|---|---|---|---|
| Male [n (%)] | 232 (83.45) | 115 (85.19) | 31 (79.49) | 64 (81.01) | 22 (88.00) | 0.693 |
| Age (years) [median (IQR)] | 34 (31–38) | 34 (31–38) | 34 (32–37) | 35 (30–38) | 33 (30–36) | 0.873 |
| CD4 count (cells/µL) [median (IQR)] | 30 (19–84) | 32 (19–84) | 26 (15–98) | 32 (17–66) | 30 (25–46) | 0.826 |
| Radiographic findings | ||||||
| Bilateral GGOs [n (%)] | 236 (84.89) | 117 (86.67) | 33 (84.62) | 65 (82.28) | 21 (84.00) | 0.857 |
| Pleural effusion [n (%)] | 69 (24.82) | 35 (25.93) | 9 (23.08) | 18 (22.78) | 7 (28.00) | 0.927 |
| Use of corticosteroid [n (%)] | 269 (96.76) | 130 (96.30) | 38 (97.44) | 77 (97.47) | 24 (96.00) | 0.956 |
| Concurrent pulmonary infections [n (%)] | ||||||
| Tuberculosis infection [n (%)] | 44 (15.83) | 23 (17.04) | 6 (15.38) | 11 (13.92) | 4 (16.00) | 0.946 |
| Fungal infection [n (%)] | 22 (7.91) | 10 (7.41) | 3 (7.69) | 7 (8.86) | 2 (8.00) | 0.986 |
| Other infection [n (%)] | 89 (32.01) | 45 (33.33) | 13 (33.33) | 23 (29.11) | 8 (32.00) | 0.931 |
| Multiple infection [n (%)] | 19 (6.83) | 10 (7.41) | 3 (7.69) | 4 (5.06) | 2 (8.00) | 0.906 |
| Symptom onset to PCP treatment (days) [median (IQR)] | 7 (3–14) | 7 (3–14) | 6 (3–13) | 7 (3–15) | 8 (4–13) | 0.912 |
IQR, interquartile range; GGO, ground‐glass opacity; PCP, pneumocystis pneumonia.